Crystalline Forms of Compound 3 for Oral Complement Factor D Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders mediated by the complement pathway, such as paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy, often require lifelong intravenous injections and do not fully address the underlying immune response, leading to residual anemia and other complications.
Innovation Solution
Development of isolated crystalline forms of Compound 3, specifically Forms A, B, and M, which are characterized by specific X-ray diffraction patterns and exhibit enhanced stability and therapeutic efficacy as inhibitors of Complement Factor D, allowing for effective treatment of PNH and C3G through pharmaceutical compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (eculizumab) are used for PNH and C3G, then complement pathway activation is inhibited, but lifelong intravenous injections are required and residual anemia persists
Solution Approach 1:
The patent changes the physical state parameter of the compound from amorphous to crystalline form, which improves stability and allows for oral administration. This parameter change enables the drug to maintain therapeutic efficacy while eliminating the need for complex intravenous injection protocols and lifelong monitoring.
Solution Approach 2:
The patent replaces the mechanical intravenous injection system with an oral administration system. The crystalline form of the compound enables oral bioavailability, substituting the complex mechanical injection process with simple oral intake, thereby reducing administration complexity while maintaining therapeutic effect.
2Ease of manufacture
If amorphous form of Compound 3 is used, then synthesis is simpler, but stability and purity are insufficient for pharmaceutical formulations
Solution Approach 1:
The patent utilizes phase transition from amorphous to crystalline form. The crystalline form is obtained through controlled crystallization processes, which enhances the stability and purity of the compound while maintaining synthesis feasibility. This phase transition resolves the contradiction between manufacturing simplicity and form stability.
Solution Approach 2:
The patent changes the physical state parameter from amorphous to crystalline, which fundamentally improves stability and purity. This parameter change enables the compound to form stable pharmaceutical formulations while the synthesis pathway remains relatively simple, addressing both requirements simultaneously.
3Reliability
If multiple morphic forms (A, B, M) are developed, then therapeutic efficacy and stability are enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent segments the crystalline form into multiple distinct morphic forms (A, B, and M), each with specific XRD patterns and therapeutic properties. This segmentation allows optimization of different forms for different therapeutic indications while maintaining a manageable manufacturing process for each individual form.
Solution Approach 2:
The patent utilizes parameter changes in crystallization conditions (temperature, solvent composition, pH) to selectively obtain different morphic forms. By controlling these parameters, the manufacturing process remains straightforward while producing the desired form with optimized therapeutic efficacy and stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline forms of Compound 3 provide stable and pure pharmaceutical formulations that effectively inhibit Factor D, offering improved therapeutic outcomes for PNH and C3G, potentially reducing the need for frequent injections and enhancing patient quality of life.
Implementation Method 1
said crystalline form is Form A and is characterized by a powder X-ray diffraction (PXRD) pattern comprising at least one 2theta values selected from 2.6±0.4°, 3.6±0.4°,and 3.8±0.4°
Data Source
Figure 1
Figure 2
Figure 3
AI summary
This invention provides stable, highly crystalline forms of Complement Factor D inhibitor Compound 3 for therapeutic applications.